NCT03556917

Brief Summary

Introduction: Gynoid hydrolipodystrophy (HLDG) or cellulitis is a subcutaneous tissue disorder, with several strategies for its treatment, such as caffeine and iontophoresis. Objective: To evaluate the effects of caffeine-associated iontophoresis for the treatment of HLDG. Methods: In a longitudinal study, participants will be evaluated for: photographic documentation, ultrasound imaging, thermography and quality of life questionnaire. If included, they will be separated into 3 randomized groups (n = 30). G1: use of base gel (n = 10); G2: use of iontophoresis and gel with caffeine (n = 10) and G3: use of iontophoresis alone (n = 10). The groups will be treated with 10 sessions, 2 times per week. After that they will be reevaluated. Statistical analysis: The software used will be the SPSS StatisticalPackage (IBM SPSS Statistics, Chicago, IL, USA). The data distribution will be analyzed by the Shapiro-Wilk test. In case of normal distribution, the data will be described as mean ± standard deviation; otherwise, as median \[interquartile range 25-75%\]. For comparison of the data, we will use ANOVA and for comparison of means the Tukey test and case not normal distribution, krulskal-Wallis test and the Dunns test. The level of statistical significance adopted will be P \<0.05. Expected contributions: It is expected that investigators can contribute to the treatment of patients with HLDG and analyze the effects of iontophoresis with caffeine, both in clinical and scientific practice, providing a method that is valid and reliable for this purpose; multidisciplinary training of highly qualified human resources and the strengthening and consolidation of a research team.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jun 2018

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 15, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 14, 2018

Completed
Same day until next milestone

Study Start

First participant enrolled

June 14, 2018

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 17, 2019

Completed
18 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 4, 2019

Completed
Last Updated

April 16, 2019

Status Verified

April 1, 2019

Enrollment Period

9 months

First QC Date

May 15, 2018

Last Update Submit

April 15, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • thickness

    change from baseline subcutaneous adipose tissue thickness at after 10 sessions

    through study completion, an average of 1 year.

Secondary Outcomes (2)

  • temperature

    through study completion, an average of 1 year.

  • score quality of life

    through study completion, an average of 1 year.

Study Arms (3)

group 1

ACTIVE COMPARATOR

topical gel base + caffeine.

Combination Product: iontophoresis + caffeine

group 2

ACTIVE COMPARATOR

iontophoresis + caffeine

Combination Product: iontophoresis + caffeine

Group 3

ACTIVE COMPARATOR

iontophoresis

Combination Product: iontophoresis + caffeine

Interventions

iontophoresis + caffeineCOMBINATION_PRODUCT

we will use cafeislaine c (caffeine) +galvanic current

Group 3group 1group 2

Eligibility Criteria

Age20 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Patients with mild to moderate cellulite diagnosis will be included, according to the validated Photonumeric scale of cellulite severity
  • Body mass index less than 30 (kg / m2)

You may not qualify if:

  • Individuals who have a deregulated menstrual cycle who are pregnant;
  • Breastfeeding or using some hormone;
  • Antibiotic medication including steroids over 1 month of treatment of skin diseases; •Sensitivity or hypersensitivity of the skin;
  • Use of the same or similar cosmetics or remedies on the glutes within 1 month;
  • Surgical procedure (liposuction and skin treatments) in the region to be treated or planning some procedure within the study period;
  • Chronic debilitating diseases such as asthma, diabetes or hypertension;
  • Atopic dermatitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rodrigo Antonio Carvalho Andraus

Londrina, Paraná, 86.041-140, Brazil

Location

Related Publications (2)

  • Hexsel DM, Dal'forno T, Hexsel CL. A validated photonumeric cellulite severity scale. J Eur Acad Dermatol Venereol. 2009 May;23(5):523-8. doi: 10.1111/j.1468-3083.2009.03101.x. Epub 2009 Feb 13.

  • Yoo MA, Seo YK, Ryu JH, Back JH, Koh JS. A validation study to find highly correlated parameters with visual assessment for clinical evaluation of cosmetic anti-cellulite products. Skin Res Technol. 2014 May;20(2):200-7. doi: 10.1111/srt.12106. Epub 2013 Sep 7.

MeSH Terms

Conditions

Cellulitis

Interventions

IontophoresisCaffeine

Condition Hierarchy (Ancestors)

Skin Diseases, InfectiousInfectionsSuppurationConnective Tissue DiseasesSkin and Connective Tissue DiseasesInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Drug Administration RoutesDrug TherapyTherapeuticsElectrophoresisElectrochemical TechniquesInvestigative TechniquesXanthinesAlkaloidsHeterocyclic CompoundsPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Rodrigo A Andraus

    Universidade Norte do Paraná

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
FACTORIAL
Model Details: It is a longitudinal and randomized
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Master student

Study Record Dates

First Submitted

May 15, 2018

First Posted

June 14, 2018

Study Start

June 14, 2018

Primary Completion

March 17, 2019

Study Completion

April 4, 2019

Last Updated

April 16, 2019

Record last verified: 2019-04

Data Sharing

IPD Sharing
Will not share

Locations